Detalhe da pesquisa
1.
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Lancet Oncol
; 21(6): 821-831, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32437664
2.
Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Target Oncol
; 17(5): 517-527, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36114955
3.
Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.
Cancer Med
; 9(20): 7453-7459, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32841541
4.
Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma.
J Gastrointest Oncol
; 7(6): 828-837, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28078107